Unlocking the Full Potential of Antibody Conjugates: AJICAP® Technology for Precise DAR Control and Emerging Modality Applications
- AJICAP® Conjugation: Leveraging site-specific technologies in next-generation ADCs to enhance clinically relevant biological properties through precise DAR control such as 1, 2, 4, 8 and higher
- AJICAP® Linker: Demonstrating a novel hydrophilic linker technology that enhances stability and enables versatile synthesis of ADCs with higher DAR numbers, even with highly hydrophilic payloads
- Application for New Modality Conjugates: Bispecific antibodies and antibody-oligonucleotide conjugates produced by fully chemical conjugation technology